Researchers observed that migraine was associated with an increased risk of developing a cochlear disorder, especially tinnitus.
Having a history of migraines may play a role in the development of cochlear disorders, according to new research published in JAMA Otolaryngology-Head & Neck Surgery. Observing 5000 participants, researchers determined that migraine was associated with an increased risk of developing a cochlear disorder, such as tinnitus, sensorineural hearing impairment, or sudden deafness.
While headache is the most commonly associated symptom of migraine, those who suffer from migraine often report abnormal sensory perception, including hearing. However, a direct correlation between the 2 had yet to be assessed prior to this study.
Noting the lack of prior evidence, the researchers wrote, “It is still unclear whether migraines might increase the risk of other cochlear disorders, including tinnitus, and/or sensorineural hearing impairment, even though migraines do not occur concurrently with cochlear disorders."
The study recruited 1056 patients recently diagnosed with migraine and 4224 controls between January 1, 1996, and December 31, 2012. Participants were identified using claims data from the Taiwan Longitudinal Health Insurance Database and were followed from the index date until the first diagnosis of a cochlear disorder, death, or the end of 2012.
The migraine cohort was followed for 6.39 years, and the controls were followed for 6.52 years. Compared with the controls, those with migraine were nearly 3 times more likely (hazard ratio, 2.83; 95% CI, 2.01-3.99) to develop a cochlear disorder. By the end of follow-up, the incidence rate of cochlear disorders was 81.4 per 1 million person-years of follow-up for those with migraine, compared with 29.4 per 1 million person-years of follow-up for controls.
According to Kaplan-Meier estimates, the cumulative incidence in the migraine cohort was 12.2%, whereas the cumulative incidence in the control cohort was 5.5%.
When stratified by cochlear disorder, tinnitus was the most commonly associated with migraine. Those with a history of migraine were more than 3 times more likely than controls to develop the disorder.
The authors noted that the correlation between migraine and cochlear disorders might be explained by shared pathophysiologic characteristics. As sleep disorders, trigeminovascular theory, neuroinflammation, and/or cortical hypersensitivity have been associated with migraine, patients with tinnitus have vagal withdrawal and/or sympathetic overactivity.
“Sleep disorders, neural inflammation, and/or damage from oxidative stress could increase the risk of tinnitus and age-related hearing impairment,” wrote the researchers. “That is, these cochleovestibular disorders might result from sleep disorders, migraine-associated vasospasm, cortical hyperexcitability, neural inflammation and/or damage from oxidative stress, or enhanced activation of the sympathetic nervous system in the limbic and autonomous brain regions.”
Reference
Hwang J, Tsai S, Liu T, et al. Association of tinnitus and other cochlear disorders with a history of migraines [published online July 12, 2018]. JAMA Otolaryngol Head Neck Surg. doi: 10.1001/jamaoto.2018.0939.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen